Estrogen receptor β deficiency enhances small intestinal tumorigenesis in ApcMin/+ mice

International Journal of Cancer

Volumn 123, Issue 2, 2008, Pages 303-311

  Giroux, Véronique ^a,b,c   Lemay, Frédéric ^a   Bernatchez, Gérald ^a,b,c   Robitaille, Yolaine ^a,b,c   Carrier, Julie C ^a,b,c  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

^c Equipe IRSC Sur l'Épithélium Digestif   (Canada)

Author keywords

ApcMin +; Colorectal cancer; Estrogen receptor ; Intestinal tumorigenesis; Microarray; TGF

Indexed keywords

BROXURIDINE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR BETA; LIGAND; RECEPTOR SUBTYPE; TRANSFORMING GROWTH FACTOR BETA; DIAGNOSTIC AGENT;

ADENOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; COLON; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; ESTROGEN RECEPTOR BETA DEFICIENCY; FEMALE; GENE EXPRESSION PROFILING; IMMUNOMODULATION; JEJUNUM; MICROARRAY ANALYSIS; MOUSE; MOUSE STRAIN; NONHUMAN; OVARIECTOMY; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SMALL INTESTINE; STEADY STATE; UPREGULATION; WILD TYPE; ANIMAL; C57BL MOUSE; COLON TUMOR; DISEASE MODEL; DNA MICROARRAY; GENE EXPRESSION REGULATION; INTESTINE TUMOR; MALE; METABOLISM; MOUSE MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOMA; ANIMALS; BROMODEOXYURIDINE; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; INTESTINAL NEOPLASMS; INTESTINE, SMALL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, MUTANT STRAINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIECTOMY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 44949170611     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23532     Document Type: Article

References (52)

1. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574-82.
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
3. Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor β on gene networks regulated by estrogen receptor α in breast cancer cells. Endocrinology 2006;147:4831-42.
4. Kudwa AE, Michopoulos V, Gatewood JD, Rissnian EF. Roles of estrogen receptors α and β in differentiation of mouse sexual behavior. Neuroscience 2006;138:921-8.
5. Murphy LC, Watson PH. Is oestrogen receptor-β a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 2006;13:327-34.
6. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERβ isoforms in colon cancer. Cancer Res 2001;61:632-40.
7. Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, Sotiropoulou-Bonikou G, Papavassiliou AG. Oestrogen receptor β (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 2003;39:1251-8.
8. Witte D, Chirala M, Younes A, Li Y, Younes M. Estrogen receptor β is expressed in human colorectal adenocarcinoma. Hum Pathol 2001;32:940-4.
9. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor β in malignant human colon. Cancer Res 2000;60:245-28.
10. Harris HA. Estrogen receptor-β: recent lessons from in vivo studies. Mol Endocrinol 2007;21:1-13.
11. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-4.
12. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668-70.
13. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular β-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995;92:3046-50.
14. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S, Hedge P. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-9.
15. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumorigenesis. Nature 1992;359:235-7.
16. Corpet DE, Pierre F. Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:39-400.
17. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M. Effect of single and compound knockouts of estrogen receptors α (ERβ) and β (ERβ) on mouse reproductive phenotypes. Development 2000;127:4277-91.
18. Andersen HL, Weis JU, Fjalland B, Korsgaard N. Effect of acute and long-term treatment with 17-β-estradiol on the vasomotor responses in the rat aorta. Br J Pharmacol 1999;126:159-68.
19. Carrier JC, Deblois G, Champigny C, Levy E, Giguere V. Estrogen related-receptor a (ERR a) is a transcriptional regulator of apolipoprotein A-IV and controls lipid handling in the intestine. J Biol Chem 2004;279:52052-8.
20. Kendziorski C, Irizarry RA, Chen KS, Haag JD, Gould MN. On the utility of pooling biological samples in microarray experiments. Proc Natl Acad Sci USA 2005;102:4252-7.
21. Labrie F, Luu-The V, Martel C, Chernomoretz A, Calvo E, Morissette J, Labrie C. Dehydroepiandrosterone (DHEA) is an anabolic steroid like dihydrotestosterone (DHT), the most potent natural androgen, and tetrahydrogestrinone (THG). J Steroid Biochem Mol Biol 2006;100:52-8.
22. Mai V, Colbert LH, Berrigan D, Perkins SN, Pfeiffer R, Lavigne JA, Lanza E, Haines DC, Schatzkin A, Hursting SD. Calorie restriction and diet composition modulate spontaneous intestinal tumorigenesis in Apc(Min) mice through different mechanisms. Cancer Res 2003;63:1752-5.
23. Plateroti M, Rubin DC, Duluc I, Singh R, Foltzer-Jourdainne C, Freund JN, Kedinger M. Subepithelial fibroblast cell lines from different levels of gut axis display regional characteristics. Am J Physiol 1998;274:G945-4.
24. Gregorieff A, Pinto D, Begthel H, Destree O, Kielman M, Clevers H. Expression pattern of Wnt signaling components in the adult intestine. Gastroenterology 2005;129:626-38.
25. Ochiai M, Watanabe M, Kushida H, Wakabayashi K, Sugimura T, Nagao M. DNA adduct formation, cell proliferation and aberrant crypt focus formation induced by PhIP in male and female rat colon with relevance to carcinogenesis. Carcinogenesis 1996;17:95-8.
26. Odagiri E, Jibiki K, Kato Y, Nakamura S, Oda S, Demura R, Demura H. Steroid receptors in dimethylhydrazine-induced colon carcinogenesis. Cancer 1985;56:2627-34.
27. Weyant MJ, Carothers AM, Mahmoud NN, Bradlow HL, Remotti H, Bilinski RT, Bertagnolli MM. Reciprocal expression of ERα and ERβ is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res 2001;61:2547-51.
28. Javid SH, Moran AE, Carothers AM, Redston M, Bertagnolli MM. Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer. Carcinogenesis 2005;26:587-95.
29. Smirnoff P, Liel Y, Gnainsky J, Shany S, Schwartz B. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol Res 1999;11:255-64.
30. Guo JY, Li X, Browning JD Jr, Rottinghaus GE, Lubahn DB, Constantinou A, Bennink M, MacDonald RS. Dietary soy isoflavones and estrone protect ovariectomized ERαKO and wild-type mice from carcinogen-induced colon cancer. J Nutr 2004;134:179-82.
31. Wada-Hiraike O, Imamov O, Hiraike H, Hultenby K, Schwend T, Omoto Y, Warner M, Gustafsson JA. Role of estrogen receptor β in colonic epithelium. Proc Natl Acad Sci USA 2006;103:2959-64.
32. Cho NL, Javid SH, Carothers AM, Redston M, Bertagnolli MM. Estrogen receptors α and β are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res 2007;67:2366-72.
33. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, Gustafsson JA. A role for estrogen receptor β in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 2001;98:6330-5.
34. Imamov O, Morani A, Shim GJ, Omoto Y, Thulin-Andersson C, Warner M, Gustafsson JA. Estrogen receptor β regulates epithelial cellular differentiation in the mouse ventral prostate. Proc Natl Acad Sci USA 2004;101:9375-80.
35. McPherson SJ, Ellem SJ, Simpson ER, Patchev V, Fritzemeier KH, Risbridger GP. Essential role for estrogen receptor β in stromal - epithelial regulation of prostatic hyperplasia. Endocrinology 2007;148:566-74.
36. Moriarty K, Kim KH, Bender JR. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 2006;147:5557-63.
37. Tremblay A, Tremblay GB, Labrie F, Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol Cell 1999;3:513-19.
38. Monroe DG, Getz BJ, Johnsen SA, Riggs BL, Khosla S, Spelsberg TC. Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERα or ERβ. J Cell Biochem 2003;90:315-26.
39. Scoane J. Escaping from the TGFβ anti-proliferative control. Carcinogenesis 2006;27:2148-56.
40. Yue J, Mulder KM. Transforming growth factor-β signal transduction in epithelial cells. Pharmacol Ther 2001;91:1-34.
41. Feng XH, Derynck R. Specificity and versatility in tgf-β signaling through Smads. Annu Rev Cell Dev Biol 2005;21:659-93.
42. Jakowlew SB. Transforming growth factor-β in cancer and metastasis. Cancer Metastasis Rev 2006;25:435-57.
43. Platet N, Cathiard AM, Gleizes M, Garcia M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 2004;51:55-67.
44. Wada K, Nomura S, Morii E, Kitamura Y, Nishizawa Y, Miyake A, Terada N. Changes in levels of mRNAs of transforming growth factor (TGF)-β1, -β2, -β3. TGF-β type II receptor and sulfated glycoprotein-2 during apoptosis of mouse uterine epithelium. J Steroid Biochem Mol Biol 1996;59:367-75.
45. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003;425:577-84.
46. Wang T, Donahoe PK. The immunophilin FKBP12: a molecular guardian of the TGF-β family type I receptors. Front Biosci 2004;9:619-31.
47. Ito Y, Miyazono K. RUNX transcription factors as key targets of TGF-β superfamily signaling. Curr Opin Genet Dev 2003;13:43-7.
48. Leboy P, Grasso-Knight G, D'Angelo M, Volk SW, Lian JV, Drissi H, Stein GS, Adams SL. Smad-Runx interactions during chondrocyte maturation. J Bone Joint Surg Am 2001;83-A(Suppl 1):S15-22.
49. Terasaka S, Aita Y, lnoue A, Hayashi S, Nishigaki M, Aoyagi K, Sasaki H, Wada-Kiyama Y, Sakuma Y, Akaba S, Tanaka J, Sone H, Yonemoto J, Tanji M, Kiyama R. Using a customized DNA microarray for expression profiling of the estrogen-responsive genes to evaluate estrogen activity among natural estrogens and industrial chemicals. Environ Health Perspect 2004;112:773-81.
50. Matsuzaki K, Seki T, Okazaki K. TGF-β during human colorectal carcinogenesis: the shift from epithelial to mesenchymal signaling. Inflammopharmacology 2006;14:198-203.
51. Muller N, Reinacher-Schick A, Baldus S, van Hengel J, Berx G, Baar A, van Roy F, Schmiegel W, Schwarte-Waldhoff I. Smad4 induces the tumor suppressor E-cadherin and P-cadherin in colon carcinoma cells. Oncogene 2002;21:6049-58.
52. Zapatka M, Zboralski D, Radacz Y, Bockmann M, Arnold C, Schoneck A, Hoppe S, Tannapfel A, Schmiegel W, Simon-Assmann P, Schwarte-Waldhoff I. Basement membrane component laminin-5 is a target of the tumor suppressor Smad4. Oncogene 2007;26:1417-27.